GSK criticised over letter to pharmacists

The ACCC has criticised the ambiguity of a letter GSK sent to pharmacists and wholesalers about the price of Panadol Osteo after it was removed from the PBS.

However, it has ruled that the letter was unlikely to have contravened consumer law. This follows a complaint by Federal Health Minister Sussan Ley that the letter contained false, misleading or deceptive claims.

In the December letter, the company wrote that it would put up the price on January 1, the day the product was taken off the PBS.

“In moving to an OTC business model, GlaxoSmithKline is no longer able to sustain its current pricing of Panadol Osteo,” the letter said.

The ACCC says it has  “significant concerns about the ambiguity of GSK’s statement”.

ACCC chairman Rod Sims said the letter did not make the reasons for the price rise clear “leaving open to interpretation” whether the